Brent O’Carrigan

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

Timothy A. Yap, Brent O’Carrigan, Marina S. Penney et al. · Journal of Clinical Oncology · 2020 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study

Edmond Atallah, Sarah J. Welsh, Brent O’Carrigan et al. · JHEP Reports · 2023 · 52 citations · Full text

Pharmacy, Oncology, Cancer Epidemiology +14

Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.

Brent O’Carrigan, Maria J. de Miguel, D. Papadatos-Pastos et al. · Journal of Clinical Oncology · 2016 · 34 citations

Medicine, Oncology, Pharmacology +14

REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers

Sophie Merrick, Matthew Nankivell, Matteo Quartagno et al. · Contemporary Clinical Trials · 2022 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

Timothy A. Yap, Maria J. de Miguel, Brent O’Carrigan et al. · Molecular Cancer Therapeutics · 2015 · 18 citations

Medicine, Oncology, Pharmacology +16